ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 286

Cardiovascular Risk In Adults With Juvenile Idiopathic Arthritis

Elizabeth Coulson1, Wan-Fai Ng2, Philip N. Platt3 and H. E. Foster4, 1Rheumatology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle upon Tyne, United Kingdom, 3Rheumatology, Freeman Hospital, Newcastle upon Tyne, United Kingdom, 4Paediatric Rheumatology, Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease and juvenile idiopathic arthritis (JIA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects I: Juvenile Idiopathic Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Increased cardiovascular mortality and morbidity have been observed in adults with Rheumatoid Arthritis. The long-term risk of cardiovascular disease for individuals with Juvenile Idiopathic Arthritis (JIA) remains uncertain. This study aims to determine whether adults with JIA have an increased risk of cardiovascular disease compared to the general population.

Methods:

51 patients with JIA (mean age 35.6 years, SD 13.23) were compared to 26 controls (mean age 37.3 years, SD 13.14). Data regarding traditional cardiovascular risk factors were collected including fasting blood glucose and lipid profile, blood pressure, BMI and history of hypertension, hypercholesterolaemia, diabetes mellitus, smoking history and family history of cardiovascular disease. Disease sub-type (ILAR criteria) and duration were recorded. In the patient group the sub-types were as follows: systemic 3/51 (5.9%), enthesitis-related arthritis (ERA) 5/51 (9.8%), extended oligoarticular 12 /51 (23.5%), polyarticular 27/51 (52.9%), juvenile psoriatic (JPSA) 4/51 (7.8%). Median disease duration was 24 years (3-57). Many (23/51 (45%)) patients were taking biological therapy, 13 as monotherapy and 10 in combination with a DMARD; a further 17/51 (33%) patients were taking one or more DMARDs. Common carotid artery intima-media thickness (CCA IMT) was examined by B-mode ultrasound (Toshiba AplioXU and 12 MHz transducer) as a surrogate marker of cardiovascular disease. Images were analysed blinded using the M’athñ software package (Intelligence in Medical Technologies). Continuous, parametric variables were analysed using the independent samples T-test, non-parametric using the Mann Whitney U test and categorical data using the chi-squared test.

Results:

The Table shows that a significantly higher proportion of patients had a pre-existing diagnosis of hypertension compared to controls (p=0.029) but no significant differences in other pre-existing traditional cardiovascular risk factors. The patient group had a significantly higher CRP (p=0.006). No significant differences were found in ESR, fasting glucose or lipid levels, BMI or systolic or diastolic blood pressures recorded in clinic.  CCA IMT showed good correlation with age (Pearson’s coefficient 0.76, p=0.000). The patient group had a significantly higher mean CCA IMT (0.54 vs. 0.49, p=0.037) compared to controls. Subgroup analysis revealed a significantly higher mean CCA IMT in those with polyarticular disease (0.56 vs. 0.48, p=0.01), but not for other subtypes. CCA IMT was not significantly higher in patients taking biologics (0.51 vs. 0.49 p=0.396) but was for those taking DMARDs (0.58 vs. 0.48, p=0.029) compared to controls.

Conclusion:

Adults with JIA were found to have an increased cardiovascular risk measured using carotid IMT compared to age- and sex-matched controls. This may in part be explained by an increased prevalence of hypertension.

Patient n=51

Control n=26

P value

Hypertension n(%)

12 (23.5)

1 (3.9)

0.029

Hypercholesterolaemia n(%)

4 (7.8)

1 (3.9)

0.501

Diabetes mellitus n(%)

2 (3.9)

1 (3.9)

0.987

Family history of cardiovascular disease n(%)

6 (11.8)

3 (11.5)

0.771

Smoking history n(%)

Ever

12 (23.5)

Ever

3 (11.5)

0.305

Never

39 (76.5)

Never

23 (88.5)

Pack Years (mean)

10.4

8.5

CRP (mg/l) mean (SD)

9.0 (9.02)

5.6 (1.97)

0.006

ESR (mm/hr) mean (SD)

12.6 (12.75)

6.4 (7.70)

0.106

BMI (kg/m2) mean (SD)

25.0 (6.5)

24.9 (4.3)

0.483

Systolic BP (mmHg) mean (SD)

122 (15.4)

120 (14.0)

0.684

Diastolic BP (mmHg) mean (SD)

79 (10.1))

78 (8.6)

0.859

Glucose (mmol/l) mean (SD)

4.9 (1.87)

4.9 (0.34)

0.496

Cholesterol (mmol/l) mean (SD)

4.6 (0.97)

4.8 (1.00)

0.417

Triglycerides (mmol/l) mean (SD)

1.04 (0.51)

1.01 (0.61)

0.374

HDL (mmol/l) mean (SD)

1.5 (0.49)

1.7 (0.45)

0.109

LDL (mmol/l) mean (SD)

2.5 (1.04)

2.6 (1.06)

0.954

CCA IMT (mm) mean (SD)

0.54 (0.10)

0.49 (0.08)

0.037

Polyarticular n=27

0.56 (0.11)

0.48 (0.08)

0.010

JPSA n=4

0.48 (0.07)

0.46 (0.02)

0.289

Systemic n=3

0.68 (0.05)

0.51 (0.07)

0.050

Extended oligoarticular n=12

0.51 (0.65)

0.46 (0.42)

0.054

ERA n=5

0.46 (0.06)

0.47 (0.09)

0.806


Disclosure:

E. Coulson,
None;

W. F. Ng,
None;

P. N. Platt,
None;

H. E. Foster,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-risk-in-adults-with-juvenile-idiopathic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology